Qualigen Net Debt vs Asset Turnover Analysis
QLGN Stock | USD 3.76 0.14 3.59% |
Qualigen Therapeutics financial indicator trend analysis is much more than just breaking down Qualigen Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Qualigen Therapeutics is a good investment. Please check the relationship between Qualigen Therapeutics Net Debt and its Asset Turnover accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.
Net Debt vs Asset Turnover
Net Debt vs Asset Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Qualigen Therapeutics Net Debt account and Asset Turnover. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Qualigen Therapeutics' Net Debt and Asset Turnover is 0.43. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of Qualigen Therapeutics, assuming nothing else is changed. The correlation between historical values of Qualigen Therapeutics' Net Debt and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Qualigen Therapeutics are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Net Debt i.e., Qualigen Therapeutics' Net Debt and Asset Turnover go up and down completely randomly.
Correlation Coefficient | 0.43 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most indicators from Qualigen Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Qualigen Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.As of the 13th of December 2024, Selling General Administrative is likely to grow to about 7.3 M, while Tax Provision is likely to drop (5 K).
2023 | 2024 (projected) | Depreciation And Amortization | 4.5K | 4.3K | Interest Income | 141.5K | 86.2K |
Qualigen Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Qualigen Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Qualigen Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 3.7M | 29.1M | 22.8M | 19.1M | 2.0M | 1.9M | |
Other Current Liab | 2.2M | 9.5M | 3.3M | 7.4M | 614.6K | 583.9K | |
Total Current Liabilities | 5.3M | 10.4M | 4.6M | 8.6M | 4.1M | 5.4M | |
Total Stockholder Equity | (1.9M) | 18.3M | 16.6M | 7.2M | (2.1M) | (2.0M) | |
Property Plant And Equipment Net | 1.7M | 1.5M | 696.1K | 1.8M | 1.8M | 0.0 | |
Net Debt | 2.1M | (23.6M) | (15.9M) | (4.3M) | 897.4K | 942.3K | |
Retained Earnings | (47.3M) | (66.8M) | (84.7M) | (103.4M) | (116.8M) | (111.0M) | |
Accounts Payable | 879.3K | 500.8K | 886.2K | 619.6K | 2.2M | 2.3M | |
Cash | 153.1K | 24.0M | 17.5M | 7.0M | 401.8K | 381.7K | |
Non Current Assets Total | 2.1M | 902.1K | 2.0M | 8.3M | 866.5K | 823.2K | |
Non Currrent Assets Other | (2.1M) | 18.3K | 18.3K | 24.0K | 866.5K | 909.8K | |
Other Assets | 29.7K | 18.3K | 18.3K | 24.0K | 1.0 | 0.95 | |
Cash And Short Term Investments | 153.1K | 24.0M | 17.5M | 7.0M | 401.8K | 381.7K | |
Common Stock Total Equity | 49.4K | 6.0K | 19.1K | 27.3 | 24.57 | 23.34 | |
Common Stock Shares Outstanding | 627K | 723.7K | 2.9M | 3.8M | 5.1M | 5.3M | |
Liabilities And Stockholders Equity | 3.7M | 29.1M | 22.8M | 19.1M | 2.0M | 1.9M | |
Other Current Assets | 98.4K | 2.7M | 1.4M | 6.1M | 765.0K | 1.4M | |
Other Stockholder Equity | 45.2M | 85.1M | 101.3M | 110.5M | 114.7M | 81.5M | |
Total Liab | 5.6M | 10.8M | 6.3M | 10.3M | 4.1M | 5.9M | |
Property Plant And Equipment Gross | 108.7K | 678.12 | 5.2M | 6.5M | 7.4M | 7.8M | |
Total Current Assets | 1.6M | 28.2M | 20.8M | 10.8M | 1.2M | 1.1M | |
Property Plant Equipment | 1.5M | 696.1K | 1.8M | 1.8M | 2.0M | 1.3M | |
Other Liab | 2.7K | 158.3K | 92.9K | 406.8K | 467.8K | 491.2K | |
Net Tangible Assets | (2.7M) | 18.1M | 16.4M | 764.4K | 879.1K | 835.1K | |
Net Receivables | 707.3K | 615.8K | 822.4K | 538.6K | 484.7K | 588.3K | |
Inventory | 660.1K | 953.5K | 1.1M | 1.6M | 1.8M | 1.1M |
Pair Trading with Qualigen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Qualigen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Qualigen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Qualigen Stock
Moving against Qualigen Stock
0.84 | BMY | Bristol Myers Squibb | PairCorr |
0.84 | GILD | Gilead Sciences | PairCorr |
0.66 | ESPR | Esperion Therapeutics | PairCorr |
0.43 | DYAI | Dyadic International | PairCorr |
The ability to find closely correlated positions to Qualigen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Qualigen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Qualigen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Qualigen Therapeutics to buy it.
The correlation of Qualigen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Qualigen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Qualigen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Qualigen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Qualigen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Qualigen Stock, please use our How to Invest in Qualigen Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Qualigen Therapeutics. If investors know Qualigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Qualigen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 3.5 K | Revenue Per Share 1.034 | Quarterly Revenue Growth 0.137 | Return On Assets (0.75) | Return On Equity (8.42) |
The market value of Qualigen Therapeutics is measured differently than its book value, which is the value of Qualigen that is recorded on the company's balance sheet. Investors also form their own opinion of Qualigen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Qualigen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Qualigen Therapeutics' market value can be influenced by many factors that don't directly affect Qualigen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Qualigen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Qualigen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Qualigen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.